ArticleGlycobiology2025
Surface plasmon resonance microscopy reveals N-glycosylation driven modulation of affinity and avidity of ErbB receptors in whole single pancreatic cancer cells.
Article in Glycobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In Vitro Characterization of Agonist and Antagonist Peptide Binding Interaction Kinetics to GLP-1R in HEK293T Cells Using Surface Plasmon Resonance Microscopy.ACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Glycans found on the ErbB family of receptors (HER1, HER2, and HER3) represent promising targets for cancer treatment. Characterization and full quantification of the bivalent kinetic interactions of therapeutic antibodies against the ErbB family of receptors directly in their native cancer cellular environment represent a unique strategy to help overcome cancer drug resistance and to the development of more effective therapeutic drugs. In this study, surface plasmon resonance microscopy (SPRM) was implemented in a unique and innovative manner to quantify the bivalent kinetic interactions of monoclonal antibodies targeting HER1 (EFGR), HER2 and HER3 directly on whole BXPC3 pancreatic cancer cells under a glycosylated (native) and deglycosylated cellular environment. Results revealed in unprecedented detail that both the single-arm affinity and double-arm stronger avidity modes of binding interaction could be observed. For bivalent Cetuximab (anti-HER1) KDs of 151 nM and 4.6 nM were observed, for bivalent Herceptin (anti-HER2) KDs of 2 nM and 0.1 nM were observed, and for bivalent anti-HER3 KDs of 13 nM and 1.3 nM were observed. However, upon enzymatic N-deglycosylation of BXPC3 cells, HER1 and HER3 demonstrated significant increase in affinity of 1000-fold and 21-fold, respectively. In contrast, HER2 kinetic interactions were negligibly influenced by cellular N-deglycosylation of BXPC3 cells. This study highlights for the first time SPRM's unique ability to characterize the bivalent heterogeneous kinetic interactions of monoclonal antibodies with ErbB receptors on whole cancer cells, and to quantify the shielding influence of pancreatic cancer cell surface N-glycosylation on these interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.